Ipsen has reached an agreement to buy five consumer healthcare products from French rival Sanofi for approximately $88 million.
The deal was spurred by requirements from the European Commission to sell certain assets from a previous deal between Sanofi and the German Boehringer Ingelheim.
Ipsen are acquiring Buscopan, Suppositoria Glycerini, Mucothiol, Mucodyne, and Prontalgine, a pain treatment that has grown at double-digit rates over the last four years.
In January, Ipsen bought Merrimack pancreatic cancer drug ONIVYDE.